Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01088815 · ClinicalTrials.gov registry record · Phase 2
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 98
- Enrollment target
NCT01088815 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 98 participants.
The verdict
NCT01088815, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 98 participants
- Enrollment target
Study Summary
This is an open-label, single arm, multi-center, Phase II trial to evaluate the progression free survival in patients with metastatic adenocarcinoma of the pancreas treated with a hedgehog inhibitor (GDC-0449) in combination with chemotherapy (gemcitabine and nab-Paclitaxel).
Interventions
- DRUG Gemcitabine, nab-Paclitaxel, GDC-0449
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2010-09-17 |
| Est. Completion | 2018-02-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01088815
The ClinicalTrials.gov registry entry for NCT01088815 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gemcitabine, nab-Paclitaxel, GDC-0449 is the first listed.
NCT01088815 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01088815 about?
NCT01088815 is a clinical study titled "Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas". This is an open-label, single arm, multi-center, Phase II trial to evaluate the progression free survival in patients with metastatic adenocarcinoma of the pancreas treated with a hedgehog inhibitor (GDC-0449) in combination with chemotherapy (gemcitabine and nab-Paclitaxel).
What is the current status of trial NCT01088815?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 98 participants. The study started on 2010-09-17. Estimated completion is 2018-02-17.
What interventions are being tested in trial NCT01088815?
The interventions under investigation include: Gemcitabine, nab-Paclitaxel, GDC-0449 (DRUG).
Who is sponsoring clinical trial NCT01088815?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.